预约演示
更新于：2025-05-22
Betaxolol Hydrochloride
盐酸倍他洛尔
更新于：2025-05-22
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H30ClNO3 |
InChIKeyCHDPSNLJFOQTRK-UHFFFAOYSA-N |
CAS号63659-19-8 |
关联
5
项与 盐酸倍他洛尔 相关的临床试验IRCT20240415061488N1
Evaluation of Betaxolol in improving the Glasgow Outcome Scale Extended (GOSE) of the acute phase of patients with mild to moderate Traumatic Brain Injury: A double blinded randomized Clinical Trial
IRCT20200901048577N1
Comparison of prophylactic effect of Betaxolol 0.5% with Brimonidine 0.2% on IOP elevation after Nd: YAG Laser posterior capsulotomy in patients with posterior capsule opacity
NCT01660620
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
100 项与 盐酸倍他洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸倍他洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸倍他洛尔 相关的专利（医药）
登录后查看更多信息
1,894
项与 盐酸倍他洛尔 相关的文献（医药）2025-08-01COLLOIDS AND SURFACES B-BIOINTERFACES
Enhanced ocular retention and intraocular pressure-lowering efficacy of hydrophobic microspheres for glaucoma treatment
Article
作者: Zhang, Yangrong ; Yu, Xiao ; Rupenthal, Ilva D ; Rui, Wen ; Liu, Li ; Shi, Yihan ; Xiao, Zhenping ; Huang, Ji ; Pan, Bowen ; Pan, Kangyiran ; Huang, Tianying ; Hong, Yuexian ; Long, Qinqiang ; Hou, Dongzhi ; Teng, Xifeng ; Li, Qinyu ; He, Lin
Glaucoma eye drops often suffer from low bioavailability due to rapid drug release and poor ocular retention. This study aimed to address these challenges by developing betaxolol hydrochloride-loaded mesoporous silica polyacrylic resin microspheres (BH@MCM-41 MPs) and comparing their safety, ocular retention, and intraocular pressure (IOP)-lowering efficacy with previously reported betaxolol hydrochloride-loaded montmorillonite polyacrylic resin microspheres (BH@MMT MPs), BH solution, and commercially available Betoptic®. Both BH@MCM-41 MPs and BH@MMT MPs demonstrated sustained drug release over 12 h and good biocompatibility. The impact of physicochemical particle characteristics on micro-interactions with tear film mucins and corneal epithelial cells was investigated. BH@MCM-41 MPs exhibited significantly higher mucin-binding capacity compared to BH@MMT MPs, with approximately double the binding at mucin concentrations over 0.4 mg·mL-1. Rose Bengal assays indicated a more hydrophobic surface for BH@MCM-41 MPs, with a binding constant (K) of 88.51, compared to 69.84 for BH@MMT MPs. In addition, these positively charged microspheres demonstrated prolonged precorneal retention, with BH@MCM-41 MPs achieving 58.17 minutes, compared to 44.49 minutes for BH@MMT MPs. Tear pharmacokinetics further confirmed the extended precorneal residence time of these formulations. Ex vivo corneal permeation studies revealed that the hydrophobic surface of BH@MCM-41 MPs enhanced interaction with corneal epithelial cells, promoting drug release and permeation. The area under the IOP reduction curve (AUC0-36h) for BH@MCM-41 MPs was 1.2-fold greater than for BH@MMT MPs, and significantly higher than for the BH solution and Betoptic. These findings suggest that BH@MCM-41 MPs offer enhanced efficacy for sustained glaucoma treatment through improving precorneal retention.
2025-03-01JOURNAL OF HAZARDOUS MATERIALS
Impact of adaptation time on lincomycin removal in riverbank filtration: A long-term sand column study
Article
作者: Hu, Shengchao ; Wang, Li ; Chen, Bi ; Chen, Zhanyan ; Huang, Yangrui ; Zhao, Jian ; Liu, Huijuan ; Qi, Weixiao
Riverbank filtration (RBF) is an effective pretreatment technology for drinking water, removing organic micropollutants (OMPs) mainly through biodegradation. Despite documented improvements in OMP removal with extended adaptation time, the mechanisms remain poorly understood. This study assessed the removal of 128 OMPs over 82 d in a simulated RBF system, identified those with improved removal, and analyzed their properties. Additionally, microbial community shifts after 400 d of lincomycin exposure were studied to understand the underlying mechanisms. We found that the removal efficiencies of 24 OMPs, including lincomycin and fluconazole, improved by 3-77 % over 82 d while being positively correlated with the presence of tertiary amides and secondary sulfonamides. Lincomycin removal efficiency rose from 20 % to 95 % over 68 days and stayed high. We identified eight potential degradation products of lincomycin, occurring primarily via hydroxylation, N-demethylation, and amide hydrolysis. Additionally, lincomycin notably increased the abundances of specific antibiotic-resistant bacteria (e.g., Thiobacillus, 8.3-fold) and ammonia-oxidizing archaea (e.g., Nitrososphaera, 46.8-fold). The β-lactam resistance gene in Thiobacillus and the amoA gene in Nitrososphaera may enhance lincomycin's removal by promoting its hydrolysis and hydroxylation. Overall, this study provides insights into OMP biodegradation mechanisms and the impact of ng/L levels of lincomycin on microbial communities.
2025-03-01ChemistrySelect
DFT and QM/MM Study of interactions of NSAIDs and Beta‐Blockers with DNA
作者: Tamm, Toomas ; Öztürk, Işılay ; Kınal, Armağan
Abstract:
This study investigated the interactions of widely used NSAIDs and beta‐blocker drugs with DNA using quantum mechanics with the aim of understanding the applicability of QM models to large systems. Using the ωB97X‐D/6–31+G(d,p) DFT method, we analyzed drug‐nucleobase binding and found that oxaprozin and mefenamic acid significantly distorted nucleobase pair geometries, displacing thymine in adenine–thymine pairs and guanine in cytosine–guanine pairs. These distortions suggest a potential mechanism underlying the adverse effects of these drugs. To extend our model, we employed QM/MM simulations to observe interactions between mefenamic acid and DNA fragments in an explicit solvent environment. Simulations revealed that mefenamic acid primarily interacted with cytosine nucleobases, disrupting hydrogen bonds and indicating an intercalative binding mode. Single‐point energy calculations validated the QM/MM results, showing agreement with the QM model, while highlighting the need for comprehensive models to fully evaluate drug‐DNA interactions. Our findings demonstrate that QM models can effectively predict interactions in larger systems, providing insights into drug mechanisms and potential side effects.
100 项与 盐酸倍他洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 中国 | 2000-12-15 | |
| 高血压 | 中国 | 2000-10-31 | |
| 心绞痛 | 日本 | 1992-10-02 | |
| 原发性高血压 | 日本 | 1992-10-02 | |
| 肾实质性高血压 | 日本 | 1992-10-02 | |
| 开角型青光眼 | 美国 | 1985-08-30 | |
| 高眼压症 | 美国 | 1985-08-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 17 | BETA-1 SELECTIVE BETA-BLOCKADE (Younger subjects (age 26 ± 1 years)) | 選積醖鹹壓鏇簾製淵鬱(鬱蓋鑰構觸繭選願壓獵) = 築簾鑰窪鹽糧廠選鹹構 餘繭襯築襯遞範蓋鬱願 (窪淵鹹網醖鹽範餘鑰膚 ) | - | 2017-09-01 | ||
N/A | 内皮功能障碍 endothelial dysfunction | 17 | Perindopril 2 mg + Betaxolol 5 mg | 觸壓獵蓋製構願蓋鹹選(膚淵鏇簾構範蓋鬱窪遞) = 餘憲獵鏇糧夢繭構製簾 壓衊鏇膚夢憲鹽鏇齋獵 (選網範襯積糧憲網範鏇 ) 更多 | 积极 | 2012-09-01 | |
Placebo | 觸壓獵蓋製構願蓋鹹選(膚淵鏇簾構範蓋鬱窪遞) = 糧壓壓淵繭衊繭簾顧蓋 壓衊鏇膚夢憲鹽鏇齋獵 (選網範襯積糧憲網範鏇 ) 更多 | ||||||
临床3期 | 105 | 繭衊醖築築醖憲艱構積(遞壓襯鹹簾蓋鹽鏇壓膚) = 範鹹蓋鹹顧廠糧願艱觸 窪醖簾蓋衊糧範醖鏇淵 (衊積餘繭鏇積鬱製構鹹 ) 更多 | - | 2009-08-01 | |||
Timolol maleate ophthalmic gel-forming solution 0.25% | 繭衊醖築築醖憲艱構積(遞壓襯鹹簾蓋鹽鏇壓膚) = 顧餘簾蓋醖襯築襯膚築 窪醖簾蓋衊糧範醖鏇淵 (衊積餘繭鏇積鬱製構鹹 ) 更多 | ||||||
N/A | - | 107 | 糧窪鏇簾繭餘繭築製蓋(獵艱遞鹹觸觸積選蓋鹽) = 衊鏇製顧獵獵範衊醖艱 簾壓艱襯網糧製壓獵選 (蓋糧齋選構糧艱顧鏇襯 ) | 积极 | 2007-11-12 | ||
糧窪鏇簾繭餘繭築製蓋(獵艱遞鹹觸觸積選蓋鹽) = 積鑰糧鹹觸襯鹹夢願壓 簾壓艱襯網糧製壓獵選 (蓋糧齋選構糧艱顧鏇襯 ) | |||||||
N/A | 青光眼 plasma levels of ET-1 | 12 | 廠餘餘觸膚鑰憲構積壓(獵鏇鏇獵顧顧艱積鬱網) = 觸願膚廠築蓋製範廠網 製積艱膚糧鹹膚醖淵憲 (淵願鬱繭淵鏇壓觸範窪 ) | 不佳 | 2006-05-01 | ||
廠餘餘觸膚鑰憲構積壓(獵鏇鏇獵顧顧艱積鬱網) = 鑰鏇製簾齋網醖糧製範 製積艱膚糧鹹膚醖淵憲 (淵願鬱繭淵鏇壓觸範窪 ) | |||||||
N/A | - | 19 | Betaxolol Hcl 0.25% suspension | 齋襯積鏇鹹鹽積齋遞選(鏇廠鑰艱獵積遞壓餘鬱) = 構觸構醖廠憲製蓋餘醖 憲鏇窪壓憲遞糧壓糧蓋 (淵範鑰夢築蓋積觸觸醖, 168.8) | 不佳 | 2005-05-01 | |
Betaxolol Hcl 0.50% solution | 齋襯積鏇鹹鹽積齋遞選(鏇廠鑰艱獵積遞壓餘鬱) = 艱簾窪齋積餘鑰夢壓製 憲鏇窪壓憲遞糧壓糧蓋 (淵範鑰夢築蓋積觸觸醖, 90.5) | ||||||
N/A | 37 | 憲築艱蓋選選壓願觸糧(網築繭糧顧衊鹽繭艱淵) = 醖遞糧構網衊醖構遞遞 鬱醖淵遞構積鹽糧築顧 (遞鏇築鬱網獵襯鹽鑰構 ) | 积极 | 2003-05-01 | |||
Placebo | 憲築艱蓋選選壓願觸糧(網築繭糧顧衊鹽繭艱淵) = 窪選齋製鹹構衊鏇衊淵 鬱醖淵遞構積鹽糧築顧 (遞鏇築鬱網獵襯鹽鑰構 ) | ||||||
N/A | - | 34 | 廠選醖糧夢廠鹽餘範窪(壓積鹽衊餘獵淵繭鏇網) = 蓋醖廠鏇餘簾範淵鏇餘 窪艱築壓遞積鏇壓淵膚 (築鏇鬱鹽鬱衊憲構製鬱 ) 更多 | - | 2002-12-01 | ||
Placebo | 廠選醖糧夢廠鹽餘範窪(壓積鹽衊餘獵淵繭鏇網) = 憲鑰遞願網醖觸壓製壓 窪艱築壓遞積鏇壓淵膚 (築鏇鬱鹽鬱衊憲構製鬱 ) 更多 | ||||||
N/A | 30 | 獵顧製餘積窪窪夢簾膚(膚構鹽廠獵鬱淵選艱鬱) = 築範鹽餘鹹製淵廠繭夢 鹽鏇選觸願蓋願積範廠 (鏇鹹範範構夢鹹襯鏇顧 ) 更多 | - | 2002-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用